Myocardial Ischemia Market , By Disease Type (Stable Angina, Unstable Angina, Silent Myocardial Ischemia, Vasospastic (Prinzmetal) Angina, Microvascular Ischemia), By Drug Class (Anti-Anginal Agents (e.g., nitroglycerin, isosorbide mononitrate), Antiplatelet Agents (e.g., aspirin, clopidogrel, ticagrelor), Anticoagulants (e.g., heparin, enoxaparin, apixaban), Beta-Blockers (e.g., metoprolol, atenolol, carvedilol), ACE Inhibitors (e.g., ramipril, lisinopril, enalapril), Angiotensin II Receptor Blockers (e.g., losartan, valsartan, telmisartan), Calcium Channel Blockers (e.g., amlodipine, diltiazem, verapamil), Nitrates (e.g., nitroglycerin spray, isosorbide dinitrate), Statins (e.g., atorvastatin, rosuvastatin, simvastatin), Late Sodium Current Inhibitors/Ranolazine (e.g., ranolazine), Thrombolytics (e.g., alteplase, tenecteplase, streptokinase)), By Route of Administration (Oral and Parenteral),By Drug Type (Branded and Generic), By End User (Hospitals, Cardiac Specialty Clinics, Diagnostic Centers, Ambulatory Surgical Centers, and Research and Academic Institutes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, Africa) - Growth Trends and Forecasts (2025-2032)